Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer, focused on exploiting specific targets on tumor cells.

Pan Cancer T

Google Maps

CrUX Dataset

CrUX Top 50m

Chief Executive Officer

Rachel Abbott

Nina Satih

European Union (EU) Therapeutics Companies

Europe Life Science Companies

European Union (EU) Startups Founded in 2020

The Netherlands Startups

Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

Seed Round - Pan Cancer

Rotterdam

Zuid-Holland

The Netherlands

Europe

Pan Cancer

Pan Cancer T–Thuja Capital: investment, 202407 seed financing round 2nd expansion totalling €4.25m incl existing investor Thuja Capital

Pan Cancer T–Scius Communications: public relations, 202407 supply service existent by Scius Communications

Pan Cancer T secures €4.25 Million in Seed Extension Round to advance next-generation T cell therapies

Pan Cancer T taking T-cell therapies into solid tumors

Pan Cancer T–Abbott R: management, 202305– CEO joined as CSO 1/23 before Enara Bio + Adaptimmune

India

Asia

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Sep 26, 2024 2:21 PM	4303bccf
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Sep 26, 2024 2:21 PM	08030e99
news processing advanced	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	869d613d
crunchbase profile	general	Oct 29, 2024 8:56 AM	75e63d1f
peers	general	Sep 26, 2024 2:21 PM	a01ca75c
news basic	general	Sep 26, 2024 2:21 PM	fedc5adf
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis	Sep 29, 2024 6:40 AM	5bdfc1a1
funding rounds analysis	company_analysis
company structure	company_analysis
logo	meta	Sep 26, 2024 2:21 PM	a3e9cdb6
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:PANCANCER-T

Pan Cancer T